Prot #INCB18424-MA-GD-301: An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

Project: Research project

Project Details

StatusActive
Effective start/end date11/28/1811/28/21

Funding

  • PAREXEL International Corporation (Prot #INCB 18424-MA-GD-301)
  • Incyte Corporation (Prot #INCB 18424-MA-GD-301)